Memantine-Related Psychotic Symptoms in a Patient With Bipolar Disorder

Canan, Fatih; Ataoğlu, Ahmet

doi:10.4088/jcp.09l05802gry

Cited by 8 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some of these agents possess hallucinogenic properties and may induce psychosis-like symptoms in focus.psychiatryonline.org subjects who have no previous history of psychosis (34,35).…”

Section: Glutamatergic Drugsmentioning

confidence: 99%

Developments in Psychopharmacology for Major Depressive Disorder

Chang¹,

Stahl²

2012

FOC

View full text Add to dashboard Cite

After years of emphasizing the same monoamine-based neurotransmitter mechanisms for treating depression, the antidepressant medication pipeline is broadening its reach. While serotonin, norepinephrine, and dopamine remain important treatment targets, researchers are working on compounds targeting their receptors in novel ways, as well as different combinations of monoaminergic actions that they hope will lead to improved efficacy and/or decreased side effects.At the same time, other researchers are focusing on completely different avenues of drug development, such as medications that target glutamate or acetylcholine neurotransmission, opioid receptors, or hormonal systems such as vasopressin and melatonin. Advances in pharmacogenetics also offer the possibility of targeting medications more specifically to individuals depending on their likelihood of response or side effects. This article outlines some promising directions for antidepressant drug development and discusses examples for each that have been undergoing testing.

show abstract

“…Some of these agents possess hallucinogenic properties and may induce psychosis-like symptoms in focus.psychiatryonline.org subjects who have no previous history of psychosis (34,35).…”

Section: Glutamatergic Drugsmentioning

confidence: 99%

Developments in Psychopharmacology for Major Depressive Disorder

Chang¹,

Stahl²

2012

FOC

View full text Add to dashboard Cite

show abstract

“…These compounds, reproducing with impressive accuracy the symptoms of schizophrenia, are characterized by slower open channel blocking/unblocking kinetics and weaker voltagedependency, 3 providing them with high affinity to the NMDA receptor and making them distinct from lower-affinity compounds, such as memantine, for which psychotic symptoms are rarely reported. 4 Because of its low cost and abuse liability, a growing trend of Zoletil abuse for recreational purposes can be expected. In addition, Zoletil use may trigger psychotic symptoms and disorganized behavior, which might be rare, but still dangerous and lifethreatening.…”

Section: Disclosure Statementmentioning

confidence: 99%

Psychosis associated with high dose of Zoletil

Huang

Cheng

Yang

et al. 2016

Psychiatry Clin Neurosci

View full text Add to dashboard Cite

“… 3 Memantine has been used as an adjuvant to treat major depressive disorder, bipolar disorder, and schizophrenia. 4 – 7 Though the mechanisms of memantine for treating psychiatric disorders remains unclear, memantine can block the NMDA receptor competitively in the frontal cortex 8 and then inhibit the function of glutamate, which further exert antidepressant effects. 9 In this case study, we reported a 73-year-old woman with vascular dementia who experienced a manic episode after taking memantine.…”

Section: Introductionmentioning

confidence: 99%

Memantine induces manic episode in a 73-year-old patient with vascular neurocognitive disorder: a case report

Duan

Lao

Chen

et al. 2018

NDT

View full text Add to dashboard Cite

Memantine, an N-methyl-d-aspartate receptor antagonist, is a well-established treatment option for moderate-to-severe cognitive impairment related to Alzheimer disease. Recently, growing evidence has indicated memantine might also be effective in treatment of affective disorders. The common drug-induced adverse events of memantine include confusion, dizziness, drowsiness, headache, insomnia, and agitation. Herein, we presented a case of a 73-year-old female patient with vascular neurocognitive disorder, who developed a manic episode after taking memantine.

show abstract

Memantine-Related Psychotic Symptoms in a Patient With Bipolar Disorder

Cited by 8 publications

References 10 publications

Developments in Psychopharmacology for Major Depressive Disorder

Developments in Psychopharmacology for Major Depressive Disorder

Psychosis associated with high dose of Zoletil

Memantine induces manic episode in a 73-year-old patient with vascular neurocognitive disorder: a case report

Contact Info

Product

Resources

About